NCT00745953View on ClinicalTrials.gov

Regression of Fatty Heart by Valsartan Therapy

PHASE4WithdrawnINTERVENTIONAL

0

Timeline

Start Date

August 31, 2007

Primary Completion Date

August 31, 2009

Study Completion Date

August 31, 2009

Conditions

Metabolic SyndromeLipotoxicity

Interventions

DRUG

Valsartan

Valsartan 320mg PO daily for 8 months

DRUG

Hydrochlorothiazide

Hydrochlorothiazide 25mg PO daily for 8 months

Trial Locations (1)

75390

University of Texas Southwestern Medical Center, Dallas

Sponsors

Collaborators (1)

Novartis Pharmaceuticals

All Listed Sponsors

collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

University of Texas Southwestern Medical Center

OTHER